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Abstract
Background: Recent consensus guidelines recommend pregabalin as a first-tier treatment for
painful diabetic peripheral neuropathy (DPN). We evaluated the efficacy of pregabalin 600 mg/d
(300 mg dosed BID) versus placebo for relieving DPN-associated neuropathic pain, and assessed
its safety using objective measures of nerve conduction (NC).
Methods: In this randomized, double-blind, placebo-controlled trial, the primary efficacy measure
was endpoint mean pain score (MPS) from daily pain diaries (11-point scale). NC velocity and
sensory and motor amplitudes were assessed at baseline, endpoint, and end of follow-up (2 weeks
post-treatment). At each timepoint, the median-motor, median-sensory, ulnar-sensory, and
peroneal-motor nerves were evaluated. Secondary efficacy measures included weekly MPS and
proportion of responders (patients achieving ≥50% reduction in MPS from baseline to endpoint).
After 1-weeks' dosage escalation, pregabalin-treated patients received 300 mg BID for 12 weeks.
Results: Eighty-two patients received pregabalin and 85 placebo. Mean durations were 10 years
for diabetes and ~5 years for painful DPN. Pregabalin-treated patients had lower MPS than controls
(mean difference, -1.28; p <.001). For all four nerves, 95% CIs for median differences in amplitude
and velocity from baseline to endpoint and baseline to follow-up included 0 (ie, no significant
difference vs. placebo). Significant pain improvement among pregabalin-treated patients was evident
at week 1 and sustained at every weekly timepoint. More pregabalin-treated patients (49%) than
controls (23%) were responders (p <.001).
Conclusion: Pregabalin 600 mg/d (300 mg BID) effectively reduced pain, was well tolerated, and
had no statistically significant or clinically meaningful effect on NC in patients with painful DPN.
Trial registration: ClinicalTrials.gov NCT00159679
Background
Diabetic peripheral neuropathy (DPN) occurs in approxi-
mately 20% of all diabetics [1], and among persons who
have had diabetes >25 years, its prevalence is about 50%.
Pathologic features of DPN include distal axonopathy,
primary demyelination, axoglial disjunction, and Walle-
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rian degeneration with a consequent loss of fiber density
[2,3]. Typical symptoms of DPN include tingling, pain,
numbness or weakness in the feet and hands; severe dys-
esthetic burning with nighttime worsening; allodynia;
insomnia; and anxiety or depression [4-7].
Pregabalin is a nonopiate that is well tolerated and
relieves painful symptoms of distal symmetrical polyneu-
ropathy with minimal risk of dependence or impact on
patients' diabetes control [8]. Pregabalin has consistently
proved an effective treatment for DPN and postherpetic
neuralgia (PHN) in its extensive clinical trial program [9-
16]. It is among the agents recommended by the American
Academy of Neurology as a Group 1 treatment for PHN
[17], and as a first-line treatment for painful polyneurop-
athy by the European Federation of Neurological Societies
[18]. Recent consensus guidelines have identified pregab-
alin as one of the first-tier treatments for painful DPN
[19,20].
The current study evaluated the efficacy and safety/tolera-
bility of pregabalin at the upper end of its recommended
dosing range (600 mg/d) and at a simpler regimen, twice
daily. The study also explored the impact of pregabalin on
sensory and motor nerve conduction (NC). In a recent
study, monotone worsening of velocity was demonstrated
to be sensitive to even subclinical progression of neurop-
athy associated with diabetes [21]. The electrophysiologic
measures employed in this study were a standard, vali-
dated, objective, and reliable measure of the functional
integrity of large diameter peripheral nerve fibers [22-24].
Methods
This was a 13-week, randomized, double-blind, placebo-
controlled, parallel-group trial performed across 23 cent-
ers in the United States. Following a 1-week baseline
phase (visit 1), patients were randomized (visit 2/visit 3,
week 0 titration initiation) to placebo or to pregabalin
600 mg/d administered as two divided doses. Daily dos-
age was escalated over a 1-week period beginning with a
single dose of 150 mg pregabalin on day 1, followed by
two doses of 150 mg pregabalin on days 2–6 and two
doses of 300 mg pregabalin on day 7 (end of titration,
visit 4) which were continued for 12 weeks (visits 4–7).
No dosage changes were allowed during the study. Fol-
lowing study endpoint (termination visit 8, week 13), at
which time pregabalin was discontinued without taper,
there was a 2-week follow-up period (visits 9 and 10), dur-
ing which no drug was administered. Patients who with-
drew from treatment early were required to complete all
termination and follow-up visit procedures.
Patients were randomly assigned to treatment according
to a computer-generated random code, which was pre-
pared by the sponsor. The sponsor distributed the
number-coded study medications to the study sites, which
were assigned using an interactive voice-response system.
Study sites also received dispensing instructions and
forms to document medication usage from the sponsor.
The sponsor, members of the study site, and the patients
were unaware of the treatment assignment. Blinding was
maintained by dispensing pregabalin and placebo in
identical capsules.
The final protocol and informed consent documentation
were reviewed and approved by the Institutional Review
Board(s) (IRB) and/or Independent Ethics Committee(s)
(IEC) at each of the investigational centers participating in
the study. This study was conducted in compliance with
the ethical principles according to the Declaration of Hel-
sinki (revised Edinburgh, 2000) and in compliance with
IRB/IEC, informed consent regulations, and International
Congress of Harmonization (ICH) Good Clinical Prac-
tices (GCP). Written informed consent was obtained prior
to the subject entering the study (before initiation of pro-
tocol-specified procedures).
Key inclusion criteria
Enrolled patients were men or women of any race ≥18
years of age. Patients must have had type 1 or type 2 dia-
betes with HbA1C ≤11% and, if on antidiabetic medica-
tion, must have been on a stable antidiabetic medication
regimen for 30 days prior to randomization. Duration of
painful DPN was required to be ≥3 months, and patients
must have scored ≥40 mm on the Short-Form McGill Pain
Questionnaire (SF-MPQ) Visual Analog Scale. (VAS) [25].
Patients were required to keep a daily pain diary, in which
they recorded their daily pain score on an 11-point (0 =
"no pain" to 10 = "worst possible pain") numeric rating
scale (NRS) [26,27]. At randomization, patients must
have completed at least four daily pain entries and had an
average daily pain score ≥4 over the past 7 days.
Key exclusion criteria
Patients with creatinine clearance rates (CLcr) of ≤60 mL/
min were excluded, as were patients with any conditions
that could confound assessment of pain due to DPN. Prior
use of potential retinotoxins (including hydroxychloro-
quine, deferoxamine, thioridazine, and vigabatrin) was a
cause for exclusion, as was the use of the following pro-
hibited medications without appropriate washout:
▪ Medications and supplements commonly used for relief
of neuropathic pain (≥7 days prior to visit 3)
▪ Antiepileptics (≥7 days prior to visit 3)
▪ Antidepressants (≥7 days prior to visit 3; except for stable
[>30 days] regimens of SSRIs for treatment of anxiety or
depression)BMC Neurology 2008, 8:33 http://www.biomedcentral.com/1471-2377/8/33
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▪ NSAIDs (including COX-2 inhibitors), dextromethor-
phan (≥1 day prior to visit 3)
Aspirin (up to 325 mg/d for cardiac and stroke prophy-
laxis), acetaminophen (up to 4 g/d), SSRIs (see above),
and benzodiazepines such as lorazepam (dosed at bed-
time with stable [>30 days] regimen for sleep problems)
were allowed.
Primary efficacy parameter
The primary efficacy instrument was the 11-point NRS in
patients' daily pain diaries. Each day on awakening,
patients described their pain during the previous 24 hours
by choosing the appropriate number from 0–10. The pri-
mary analysis compared endpoint mean pain score (cal-
culated as the mean of the last seven available diary
entries while on double-blind study drug, including diary
entry on the day after the last dose) between pregabalin
and placebo groups. Analysis of covariance (ANCOVA)
was used with treatment and center in the model and
baseline mean pain score (mean of the last seven diary
entries prior to taking study drug, including diary entry on
day 1) as covariate. The definition of endpoint mean pain
constituted a last observation carried forward (LOCF)
approach for patients who did not complete the study.
Analysis using baseline observation carried forward
(BOCF) for noncompleters was performed as a sensitivity
analysis.
Supplemental analyses
Weekly mean pain scores were evaluated using ANCOVA,
with the same main effects model as for endpoint, as a
supplemental analysis. Proportion of responders – those
patients with ≥50% reduction in mean pain score from
baseline to endpoint – was compared between pregabalin
and placebo groups using the Cochran-Mantel-Haenszel
procedure, adjusting for center.
Secondary efficacy parameters
Patients evaluated pregabalin's effect on pain-associated
sleep interference using an 11-point NRS (0 = "pain did
not interfere with sleep" to 10 = "pain completely inter-
fered with sleep") recorded in daily sleep diaries. Analyses
of endpoint and weekly sleep-interference scores were
performed as described above for mean pain scores.
As an additional measure of patients' pain and its charac-
teristics, the SF-MPQ was administered at screening, rand-
omization, and weeks 1, 5, 9, and 13. The questionnaire
includes 15 descriptors, each ranked by patients on a 4-
point intensity scale, as well as the 100-mm VAS and the
6-point Present Pain Intensity (PPI) index. Sensory, affec-
tive, and total scores for pain descriptors; VAS score; and
PPI were analyzed separately at endpoint and by visit
using ANCOVA with treatment and center in the model
and using the scores at randomization as the covariate.
To gauge global improvement, the Clinical and Patient
Global Impression of Change scales (CGIC and PGIC)
[28] were administered at endpoint. Both scales were ana-
lyzed using modified ridit transformation with the
Cochran-Mantel-Haenszel procedure, adjusting for
center.
Primary safety parameter
The primary safety parameter was nerve conduction (NC),
assessed at three timepoints during the study – baseline,
endpoint, and follow-up. At each timepoint, replicate
measures (at least 1 calendar day apart [maximum of 7
calendar days apart]) were taken to reduce variability.
Mean NC measures were compared at baseline and end-
point to determine whether there was any change in NC
within large, myelinated nerve fibers during the study. NC
testing was performed during follow-up to determine
whether any NC deficits that may have been observed at
endpoint would be reversible after 2 weeks off study med-
ication. All patients were to complete the follow-up NC
testing, regardless of whether they completed the study.
No imputation was done for NC values that were missing
as a result of technical error, were not performed, or per-
formed outside of allowable time frames. For measure-
ments recorded as physiologically absent ("no response,"
meaning outside detection sensitivity of the test), non-
zero values were imputed using the 1st percentile of all
non-missing values across all visits, all patients, and all
treatment groups. This was done to impute the low end of
the range of detectable values while avoiding undue influ-
ence by outliers.
Amplitude and conduction velocity were assessed for the
peroneal motor nerve, median motor nerve, median sen-
sory nerve, and ulnar sensory nerve using standard surface
recording procedures [29]. Amplitude was measured from
baseline-to-peak in millivolts (mV) for the muscles inner-
vated by the motor nerves and in microvolts (μV) for
direct measure of sensory nerves. Conduction velocity was
measured in meters per second (m/s) and was recorded at
the onset of response. NC data were recorded on patients'
left sides (unless contraindicated). Skin temperature was
to be maintained at ≥32.0°C (89.6°F) in the arm and at
≥31.0°C (87.8°F) in the leg throughout testing; if neces-
sary, warming techniques were allowed to achieve mini-
mum skin temperatures. Surface temperatures were taken
several minutes after warming to allow stabilization [30].
Presence of peripheral edema in the limb was to be noted
at the time of NC testing.BMC Neurology 2008, 8:33 http://www.biomedcentral.com/1471-2377/8/33
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Analysis
Change from baseline to endpoint and from baseline to
follow-up was computed for each NC parameter. Differ-
ences in medians between treatment groups and the cor-
responding 95% confidence intervals (CIs) were
provided; the CIs were computed using Campbell's and
Gardner's algorithm [31]. If the CIs at endpoint included
0, this suggested the effect of pregabalin on NC parame-
ters was no different from that of placebo. For each
parameter, patients with possible outlying changes (any
value ≤ the 5th percentile) were identified for each treat-
ment group at endpoint and follow-up, and these changes
were reviewed for clinical relevance.
Additional safety measures
In addition to NC parameters, safety and tolerability were
evaluated by collection of all observed or volunteered
adverse events (AEs). Severity was assessed as mild, mod-
erate, or severe, and investigators' opinions of the relation
of observed or volunteered AEs to treatment were
recorded. Serious AEs were those that resulted in death,
were life-threatening, required inpatient hospitalization
or prolongation of existing hospitalization, resulted in a
persistent or significant disability/incapacity, or resulted
in congenital anomaly/birth defect.
AEs of special interest
Detailed assessments of edema were regularly made, at
baseline and weeks 1, 5, 9, and 13. Peripheral edema was
quantified as absent, trace, pitting +1, pitting +2, pitting
+3, and patients were assessed for the presence or absence
of facial and generalized edema. Additionally, a simpler
edema assessment (absent or present in the limb tested)
was performed in conjunction with NC testing, so edema
was assessed (either in detail or simply) at every study
visit. Weight change was assessed in two ways: spontane-
ous reports of weight change as an AE by patients and
objective measure of weight change ≥7% from baseline to
endpoint.
Laboratory evaluations included hematology, chemistry,
urinalysis, CLcr, thyroid-stimulating hormone, glyco-
sylated hemoglobin (HbA1c), and serum pregnancy test-
ing. Neurologic and physical examinations were
performed. Clinically significant changes in physical
examination findings and abnormal laboratory findings
were noted.
Results
Patient disposition
Of 326 patients who entered baseline, 167 were rand-
omized and received study medication (representing the
intent-to-treat [ITT] population, Figure 1). The most fre-
quent reason patients were not randomized was failure to
meet entry criteria (133/159). One hundred fifteen
patients completed double-blind treatment, and 139
completed follow-up. The percentages of discontinua-
tions during the double-blind phase were similar: pregab-
alin (34%) and placebo (28%). Most of these withdrawals
were due to AEs, with 17% discontinuing pregabalin and
12% discontinuing placebo. During follow-up, AEs were
again the most common reason for withdrawal, with 9%
discontinuing from the pregabalin and 6% discontinuing
from the placebo groups.
Patients in the two treatment groups were well matched
for demographic and baseline characteristics (Table 1).
Patients' use of prior and concomitant medications for
diabetes control were also similar between treatment
groups: 81 of 85 patients in the placebo group were taking
antidiabetic medications, including metformin/met-
formin HCl (48%), glipizide (18%), pioglitazone (15%),
and insulin (15%), whereas 76 of 82 patients in the pre-
gabalin group were taking antidiabetic medications,
including metformin/metformin HCl (50%), glipizide
(23%), pioglitazone (22%), insulin (11%), and rosiglita-
zone/rosiglitazone maleate (13%). Seven patients in the
placebo group and 6 in the pregabalin group used con-
comitant acetaminophen for pain during the study as
allowed per protocol.
Primary efficacy parameter
Treatment with 600 mg/d pregabalin (300 mg BID)
resulted in improvement, compared with placebo, in end-
point mean pain score: for pregabalin, endpoint mean
pain score was 3.54, whereas for placebo, it was 4.82, for
a treatment difference = -1.28 (95% confidence interval
[CI], -1.96 to -0.60; p = .0003). Using BOCF as a sensitiv-
ity analysis, pregabalin was also superior to placebo (end-
point mean scores, 4.32 and 5.03, treatment difference =
-0.71; 95% CI, -1.39 to -0.03; p = .0417).
Supplemental analyses of the primary efficacy parameter
included weekly mean pain scores and proportion of
responders. Improvement in the pregabalin group was
evident at week 1 (p <.0001), the first timepoint evalu-
ated, and this improvement was maintained at every
weekly timepoint through week 13 (Figure 2; p ≤.03). At
endpoint, a greater proportion of patients in the pregaba-
lin group (49%) met the responder criterion (≥50%
reduction in mean pain score from baseline to endpoint)
than did those in the placebo group (23%; p <.001).
Secondary efficacy parameters
Several secondary efficacy parameters were evaluated,
including sleep interference, the SF-MPQ, and the CGIC
and PGIC. Pregabalin was associated with greater
improvement in mean sleep interference scores compared
with placebo at endpoint (2.64 vs. 3.72, treatment differ-
ence, -1.08; 95% CI, -1.75 to -0.41; p = .0019). This signif-BMC Neurology 2008, 8:33 http://www.biomedcentral.com/1471-2377/8/33
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icant improvement was first observed at week 1 and was
maintained at every weekly timepoint except for weeks 9
and 10.
SF-MPQ
The SF-MPQ was administered at screening, randomiza-
tion, and weeks 1, 5, 9, and 13, and was analyzed sepa-
rately at each week as well as at endpoint (last
observation). On the SF-MPQ sensory, affective, and total
scores, numerical comparisons consistently favored pre-
gabalin over placebo. Significant treatment differences
were seen at weeks 1 (-5.05; 95% CI, -6.82 to -3.29; p
<.0001), 5 (-2.93; 95% CI, -5.04 to -0.82; p = .0068), and
9 (-2.62; 95% CI, -5.20 to -0.04; p = .0464) in the sensory
score. On the affective score, a significant treatment differ-
ence was seen at week 1 (-1.12; 95% CI, -1.86 to -0.37; p
= .0036). For the total score, significant treatment differ-
ences from placebo were observed at weeks 1 (-6.13; 95%
CI, -8.45 to -3.81; p <.0001) and 5 (-3.43; 95% CI, -6.23
to -0.64; p = .0163).
The SF-MPQ VAS yielded results consistent with those
reported above for mean pain score as recorded on the 11-
point NRS in patients' daily pain diaries. Pregabalin was
Patient disposition Figure 1
Patient disposition.
Screened
(N=326)
Randomized
(n=167)
ITT
(n=167)
Placebo
(n=85)
Pregabalin 600 mg/d
(n=82)
Completed double blind
(n=61, 71.8%)
Completed double blind
(n=54, 65.9%)
Entered open label
(n=55, 64.7%)
Entered open label
(n=49, 59.8%)
Not randomized  (n=159, 48.8%) 
Did not meet criteria  (n=133, 40.8%)
Adverse event  (n=0)
Other/administrative (n=26,  8.0%)
Withdrawn during double blind  (n=28, 34.1%)
Adverse event  (n=14, 17.1%)
Lack of compliance  (n=3, 3.7%)
Lack of efficacy  (n=4, 4.9%)
Lost to follow-up  (n=1, 1.2%
Other (n=6,    7.3%)
Withdrawn during double blind  (n=24, 28.2%)
Adverse event  (n=10, 11.8%)
Lack of compliance  (n=1, 1.2%)
Lack of efficacy  (n=5, 5.9%)
Lost to follow-up  (n=3, 3.5%)
Other/administrative (n=5,    5.9%)
Completed follow-up
(n=72, 84.7%)
Withdrawn during follow-up  (n=13, 15.3%)
Adverse event  (n=5, 5.9%)
Lack of compliance  (n=1, 1.2%)
Lost to follow-up  (n=3, 3.5%)
Other (n=4,    4.7%)
Completed follow-up
(n=67, 81.7%)
Withdrawn during follow-up  (n=15, 18.3%)
Adverse event  (n=7, 8.5%)
Lack of compliance  (n=2, 2.4%)
Lost to follow-up  (n=1, 1.2%)
Other (n=5,    6.1%)BMC Neurology 2008, 8:33 http://www.biomedcentral.com/1471-2377/8/33
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significantly better than placebo at each timepoint meas-
ured, with the following treatment differences: week 1 = -
16.61 (95% CI, -22.85 to -10.36; p <.0001); week 5 = -
13.94 (95% CI, -21.98 to -5.90; p = .0008); week 9 = -
14.43 (95% CI, -23.09 to -5.76; p = .0013); week 13 = -
12.40 (95% CI, -22.55 to -2.25; p = .0173); endpoint = -
11.06 (95% CI, -18.89 to -3.22; p = .0060).
For the PPI, treatment differences from placebo, favoring
pregabalin, were seen at week 1 (-0.68; 95% CI, -0.97 to -
0.39; p <.0001), week 5 (-0.39; 95% CI, -0.74 to -0.04; p
= .0294), and at endpoint (-0.34; 95% CI, -0.65 to -0.03;
p = .0311).
Global improvement was evaluated with the CGIC and
PGIC. On both the clinician-rated and the patient-rated
instruments, there was a difference in response favoring
pregabalin compared with placebo (CGIC, p = .0294;
PGIC, p = .0020) (Figures 3A and 3B).
Nerve conduction parameters
Over 13 weeks of treatment with pregabalin, patients
showed no clinically significant changes in nerve conduc-
tion measurements (Figures 4A and 4B).
Median differences in NC velocity between pregabalin
patients and placebo patients in change from baseline to
endpoint and change from baseline to follow-up ranged
from -0.8 to 0.3 m/s (Figure 5). For each of the 4 nerves
assessed, the effect of pregabalin on nerve amplitude and
velocity was not significantly different from placebo. Fur-
ther, none of the changes in NC velocity approached clin-
ical significance, which has been defined, based on a
comparative change in the neurologic examination, as a
value ranging from 2.2 to 2.9 m/s [32]. More recent dis-
cussions with the FDA have placed the boundary of "clin-
ical significance," for the purpose of calculating statistical
power, as a change in velocity ranging from 1.2–1.5 m/s
(Joseph C. Arezzo, personal communication). The
Table 1: Patient characteristics
Placebo (n = 85) Pregabalin (n = 82)
Male, n (%) 45 (52.9) 58 (70.7)
Race, n (%)
White 61 (71.8) 62 (75.6)
Black 12 (14.1) 9 (11.0)
Hispanic 12 (14.1) 9 (11.0)
Other 0 2 (2.4)
Age, years
Mean (SD) 58.3 (10.9) 58.2 (9.6)
Median 60 59.5
Range (min-max) 32–86 31–79
Body Mass Index, (kg/m2)
Mean (SD) 35.8 (8.4) 36.6 (8.3)
Range (min-max) 21.7–61.9 23.5–60.2
Weight, kg
Mean (SD) 105 (23) 107 (24)
Median 104 102
Range (min-max) 59–174 61–182
Diabetes type, n (%)
Type 1 9 (11) 4 (5)
Type 2 76 (89) 78 (95)
Duration of diabetes, years
Mean (SD) 10.3 (8.6) 10.3 (8.2)
Median 7.5 8.8
Range (min-max) 0.3–42.2 0.6–42.8
Duration of painful DPN, years
Mean (SD) 4.4 (3.7) 4.9 (3.4)
Median 3.5 4.5
Range (min-max) 0.3–18.4 0.3–14.8
Distribution of pain, n (%)
Lower extremities 85 (100) 82 (100)
Upper extremities 37 (44) 32 (39)
Baseline mean pain score
Mean (SD) 6.58 (1.58) 6.28 (1.47)
Median 6.57 6.14
Range (min-max) 3.71–10.00 3.57–9.71BMC Neurology 2008, 8:33 http://www.biomedcentral.com/1471-2377/8/33
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median changes in velocity across all nerves in the present
study were substantially less for the pregabalin group than
even these more liberal definitions of clinical significance.
In summary, there were no statistically significant or clin-
ically meaningful deficits in NC measures associated with
pregabalin at a dose clearly efficacious in treating pain
(i.e., 600 mg/day).
During the course of the study, the ulnar sensory nerve
showed the largest change in median difference between
treatment groups. A -0.8 m/s median difference (95% CI,
-2.10 to 0.40) in ulnar sensory nerve conduction velocity
was observed between treatment groups from baseline to
endpoint, with a 0.3 m/s median difference (95% CI, -
0.90 to 1.65) from baseline to follow-up. When compared
with baseline rather than with placebo, there was minimal
actual change in the pregabalin group (i.e., median of -
0.35 m/s to endpoint and 0.00 to follow-up).
Although the median changes from baseline were small
and non significant, the direction of change in NC meas-
ures favored the placebo group in all but 1 measure (ulnar
sensory amplitude). Because baseline values were higher
for the pregabalin group than for the placebo group in
most cases, this could (at least partially) reflect regression
to the mean. Differences in scores between the two study
groups were often small in absolute value (e.g., a fraction
of a μV for sensory amplitude or <0.5 m/s for motor veloc-
ities) and were relatively small compared with the
observed variance.
Safety and tolerability
Pregabalin was generally well tolerated. The percentage of
patients with ≥1 AEs was similar in the pregabalin (84%)
and placebo (78%) groups. There were more associated
AEs among the pregabalin group than the placebo group
(72% vs. 51%), and incidence of the most frequent asso-
Weekly least-squares mean pain scores Figure 2
Weekly least-squares mean pain scores.
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CGIC (A) and PGIC (B) scores Figure 3
CGIC (A) and PGIC (B) scores.
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Mean nerve amplitude (A) and nerve conduction (B) in patients treated with 600 mg/d pregabalin Figure 4
Mean nerve amplitude (A) and nerve conduction (B) in patients treated with 600 mg/d  pregabalin or placebo.
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ciated AEs was higher in the pregabalin than placebo
groups: peripheral edema (37%, 32%), dizziness (33%,
6%), weight gain (15%, 1%), and somnolence (13%, 6%)
(Table 2). The maximum intensity of most AEs was mild
or moderate in both groups, and the percentage of
patients with severe AEs was similar in both groups (pre-
gabalin, 10%; placebo, 8%). No patient died during the
study. Four patients in the pregabalin group had serious
AEs, and one withdrew from the study, whereas in the pla-
cebo group, eight patients had serious AEs, and six with-
drew from the study. None of these serious AEs were
considered associated with treatment, and all patients
who experienced serious AEs recovered from the events.
Rates of discontinuations due to AEs were similar among
the pregabalin (17% [14/82]) and placebo (12% [10/85])
groups; however, a greater proportion of AEs leading to
discontinuation in the pregabalin group were considered
associated with study drug (16% vs. 2%). In the pregaba-
lin group, no single AE accounted for more than five
patient discontinuations: peripheral edema (5, 6.1%) and
dizziness and somnolence (3, 3.7% for each) were the
most commonly cited AEs leading to discontinuation (for
each patient, more than one AE could have been cited as
a cause of discontinuation). Among study completers,
median duration of any AE was similar for patients in the
pregabalin (23.5 days) and placebo (29.0 days) groups,
though for frequently occurring AEs (peripheral edema,
dizziness, and somnolence), the median duration was
longer in the pregabalin than in the placebo group.
Weight gain was spontaneously reported as an AE by 18%
of pregabalin-treated patients and 4% of placebo patients.
The AE was generally considered associated with treat-
ment. Two pregabalin-treated patients withdrew due to
weight gain as an AE, but no case of weight gain was
Median differences in nerve conduction parameters between treatment groups: pregabalin 600 mg/d vs. placebo Figure 5
Median differences in nerve conduction parameters between treatment groups: pregabalin 600 mg/d vs. pla-
cebo.
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reported as an SAE. The percentage of patients with a ≥7%
weight gain was higher in the pregabalin group (11%)
than in the placebo group (2%).
Neurologic and physical examinations revealed no mean-
ingful differences between patients treated with pregaba-
lin and those receiving placebo. Overall, there were no
clinically meaningful changes in laboratory values over
the course of the study. Further, diabetes control appeared
to be unaffected by study medication. There was a median
change of 0 in glycosylated hemoglobin (HbA1c) for
patients in both the placebo (n = 70) and pregabalin (n =
71) treatment groups (mean change was 0.0029% for pla-
cebo patients and -0.07% for pregabalin patients).
Discussion
At a dosage of 600 mg/d (given 300 mg BID) – represent-
ing the upper end of its dosing range – pregabalin showed
robust efficacy for the treatment of painful DPN and pain-
associated sleep interference, and it was generally well tol-
erated. These efficacy and safety findings are consistent
with those reported in the literature from previous rand-
omized, controlled trials of pregabalin 150 to 600 mg/d
administered TID or BID as treatment of painful DPN [9-
12,16]. In these earlier studies, significant improvement
in pain scores was seen by week 1 [9,10,12] or 2 [9-11,16];
all studies showed significant improvement in sleep inter-
ference scores. In the current study, significant differences
from placebo in pain and sleep interference were observed
at week 1, and these significant improvements were main-
tained continuously through endpoint for pain scores and
at every timepoint, except weeks 9 and 10, for sleep inter-
ference.
Results from this 13-week, randomized, double-blind
study also demonstrated that pregabalin had no statisti-
cally significant or clinically meaningful effect on nerve
conduction when dosed at 600 mg/d. Median differences
between treatment groups in change from baseline to end-
point and change from baseline to follow-up for all four
nerves assessed ranged from -0.8 to 0.3 m/s, with 95% CIs
for median differences in amplitude and velocity from
baseline to endpoint or to follow-up including 0 in each
case. Measure of maximal nerve conduction velocity
exclusively reflects changes in large diameter myelinated
axons [24], while the pain associated with DPN princi-
pally reflects dysfunction in small diameter or unmyli-
nated axons (ie., C-fibers). The NC measures in the
present study were included as a safety measure to evalu-
ate the possibility that pregabalin relieves neuropathic
pain by causing a broad-based peripheral neuropathy. The
findings from the current study demonstrate that pregab-
alin does not achieve its therapeutic effect of relieving
neuropathic pain by damaging or otherwise adversely
affecting nerves or nerve function.
Patients responded well to pregabalin; more than twice as
many pregabalin (49%) as placebo patients (23%) real-
ized ≥50% improvement in their pain. This finding is con-
sistent with, and the proportion is numerically greater
than, responder rates from previous trials of pregabalin
that included a fixed-dosage group receiving 600 mg/d, in
which proportions of responders ranged from 39% to
48% [10,11,16]. On both clinician- and patient-rated glo-
bal impressions of improvement, the pregabalin group
scored significantly better than the placebo group.
The safety/tolerability profile in this study was generally
consistent with previous studies. Most AEs were mild or
moderate, with a low incidence of severe AEs and of seri-
ous AEs. The overall discontinuation rate and the discon-
tinuation rate due to AEs in the pregabalin treatment
group (i.e., 600 mg/day) were within the range of those
observed in previous DPN studies at a fixed dose of 600
mg/day [10-12,16]. As in previous trials of pregabalin,
dizziness, somnolence, peripheral edema, and weight
gain were among the most frequently reported AEs, and
they were typically of limited duration. The major differ-
ence in AE profile between this and previous trials was
that peripheral edema was reported at a higher rate, a find-
ing that we attribute to the difference in procedure for
assessment of this AE in this trial. Previous investigations
have shown that the frequency of peripheral edema was
higher in patients taking pregabalin with a thiazolidinedi-
one antidiabetic agent and did not appear to be attributa-
ble to other factors [33].
In previous fixed-dosage studies of pregabalin for painful
DPN that included a 600-mg/d treatment group, the inci-
dence of peripheral edema for the 600 mg/d pregabalin
group ranged from 10% to 17% and for the placebo group
Table 2: Most common adverse events considered associated 
with treatment occurring in ≥3% of either treatment group*
Placebo (n = 85)
Incidence, n (%)
Pregabalin (n = 82)
Incidence, n (%)
Peripheral edema 27 (31.8) 30 (36.6)
Dizziness 5 (5.9) 27 (32.9)
Weight gain 1 (1.2) 12 (14.6)
Somnolence 5 (5.9) 11 (13.4)
Asthenia 1 (1.2) 8 (9.8)
Ataxia 0 4 (4.9)
Dry mouth 1 (1.2) 4 (4.9)
Abdomen enlarged 4 (4.7) 3 (3.7)
Edema 0 3 (3.7)
Euphoria 0 3 (3.7)
Thinking abnormal 0 3 (3.7)
*Associated AEs are those considered by the investigator as possibly, 
probably, or definitely related to study drug and those with 
insufficient information to determine a relationship.BMC Neurology 2008, 8:33 http://www.biomedcentral.com/1471-2377/8/33
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from 2% to 5% [10,11,16]. Of note, the protocol for the
current trial required investigators to check for peripheral
edema at each visit and to assess whether to report any
increase in peripheral edema as an AE. Investigators were
not required to report observed edema as an AE if they did
not feel it met reporting criteria. This frequent, regular
assessment specifically for peripheral edema contributed
to the possible ascertainment bias that may help explain
the comparatively higher incidence – among both prega-
balin and placebo groups – observed in this trial.
This trial is an important addition to the pregabalin and
neuropathic pain literature. The robust efficacy demon-
strated by pregabalin, together with the lack of effect on
nerve conduction, confirm that pregabalin's therapeutic
effect on neuropathic pain is not achieved by altering
nerve conduction. This finding further elucidates the anal-
gesic activity of pregabalin while substantiating previous
findings surrounding the safety of pregabalin as treatment
of painful DPN. Additionally, the AE profile emerging
from this trial, along with the rapid onset of robust effi-
cacy associated with pregabalin, supports the general tol-
erability of a more convenient BID dosing schedule – as
opposed to a TID dosing schedule – in painful DPN.
Conclusion
Pregabalin 600 mg/d (300 mg BID) effectively reduced
pain, was well tolerated, and had no statistically signifi-
cant or clinically meaningful effect on NC in patients with
painful DPN.
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